Pricing regulations rile French drug companies

Plans to reduce spending on medicines will adversely affect France’s attractiveness as an R&D hub, the country’s pharmaceutical companies have said.

On 29 September the government published a plan to reduce social security spending, which includes the goal of reducing spending on medicines by nearly €1 billion by fixing new pricing regulations.

The same day, Leem, the French pharmaceutical and biotechnology industry association, published a statement saying that the government was asking drug companies to make their “greatest ever contribution” to balancing the country’s books.